Barrett's Esophagus Risk Factors in Patients Without Gastroesophageal Reflux: A Large Population-Based Study
- PMID: 38670476
- PMCID: PMC11424263
- DOI: 10.1016/j.cgh.2024.03.034
Barrett's Esophagus Risk Factors in Patients Without Gastroesophageal Reflux: A Large Population-Based Study
Abstract
Esophageal adenocarcinoma (EAC) is a lethal malignancy with an abysmal 5-year survival rate of <20%.1 Barrett's esophagus (BE) is the only known precursor to EAC.1,2 BE is characterized by intestinal metaplasia of the distal esophagus, typically arising in the setting of gastroesophageal reflux disease (GERD).1 Hence, chronic GERD symptoms are an essential criterion for BE screening in most gastroenterology guidelines, alongside other BE risk factors including age >50 years, male sex, White race, history of tobacco smoking, hiatal hernia (HH) diagnosis, obesity, and family history of BE/EAC in first-degree relatives.1,3 Dysplastic BE and early stage EAC are amenable to endoscopic eradication therapy, highlighting the importance of BE/EAC screening and surveillance.4.
Copyright © 2024 AGA Institute. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
PGI: Research funding from Exact Sciences, Castle Biosciences, CDX Medical and Pentax Medical, Consultant for Exact Sciences, Castle Biosciences, CDX Medical and Pentax Medical
JBK: Listed as an inventor of Mayo Clinic intellectual property in the field of Barrett’s esophagus detection which is licensed to Exact Sciences (Madison WI); he has received research support from Exact Sciences, paid to Mayo Clinic.
The remaining authors disclose no conflicts of interest.
References
-
- Saha B, Vantanasiri K, et al. Clin Gastroenterol Hepatol 2023:S1542–3565(23)00848–0.
-
- Sawas T, et al. Clin Gastroenterol Hepatol 2021:S1542–3565(21)01152–6.
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources